Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS

November 2nd 2022

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

European Commission Grants Orphan Drug Designation to Selinexor for Myelofibrosis

November 1st 2022

The European Commission has granted an orphan drug designation to selinexor for the treatment of patients with myelofibrosis.

Luspatercept Improves Transfusion Independence in Very Low– to Intermediate-Risk MDS

October 31st 2022

Luspatercept generated a statistically significant improvement in red blood cell transfusion independence with concurrent hemoglobin increase vs epoetin alfa in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who require RBC transfusions, meeting the primary end point of the phase 3 COMMANDS trial.

Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis

October 24th 2022

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis

October 11th 2022

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Luspatercept Demonstrates Long-Term Anemia Benefit in Lower-Risk MDS

October 7th 2022

Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.

Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera

October 7th 2022

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Momelotinib Improves OS in Patients With Myelofibrosis and Low Platelet Counts

October 3rd 2022

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Dr. Ali on Ruxolitinib and Navitoclax Combination Therapy in Myelofibrosis

September 30th 2022

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

GB2064 Reduces the Level of Bone Marrow Fibrosis in Myelofibrosis

September 30th 2022

Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.

Rusfertide Leads to Promising Phlebotomy Reduction in Polycythemia Vera

September 30th 2022

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

Dr. Kuykendall on Prognostication Factors in Myelofibrosis

September 29th 2022

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

Dr. Mascarenhas on the Investigation of Pelabresib in Myelofibrosis

September 23rd 2022

John O. Mascarenhas, MD, discusses the investigation of pelabresib in myelofibrosis.

FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

September 19th 2022

Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.

Azacitidine/Venetoclax Combo Delivers Promising Early Results in High-Risk CML, MDS

September 8th 2022

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Emavusertib Is Active in Heavily Pretreated AML and High-Risk MDS With Targeted Mutations

September 7th 2022

Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.

New JAK Inhibitors and Emerging Novel Agents Expand Myelofibrosis Treatment Arsenal

September 6th 2022

A panel of hematology cancer experts discuss the current treatment landscape and novel emerging therapies for patients with myelofibrosis.

FDA Allows Trial Enrollment to Resume for Single-Agent Emavusertib in AML/MDS

August 30th 2022

The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS

August 30th 2022

Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.

Investigators Validate Role of Liquid Biopsy in Predicting Chromosomal Abnormalities in Myeloid Neoplasms

August 24th 2022

Liquid biopsy using targeted next-generation sequencing for early diagnosis and monitoring of patients with myeloid neoplasms is effective and detects chromosomal structural abnormalities.